Annotating MYC Status in Treatment-Resistant Metastatic Castration-Resistant Prostate Cancer with Gallium-68 Citrate PET
Technical Report,01 Sep 2017,31 Aug 2018
University of California San Francisco San Francisco United States
Pagination or Media Count:
We are the first group to clinically investigate transferrin-based PET imaging in advanced prostate cancer with the use of gallium citrate PET as a non-invasive imaging biomarker of MYC activity. To date, we have successfully completed 40 whole body gallium citrate PET scans in 30 patients. 10 of the 30 patients enrolled have completed paired baseline and post treatment initiation scans following treatment with either BET bromodomain inhibition or other standard of care therapies. We have successfully completed the interim analysis demonstrated acceptable safety of the imaging tracer and preliminary evidence of the diagnostic and predictive utility of gallum citrate PET in abiraterone-resistant metastatic castration resistant prostate cancer mCRPC.
- Medicine and Medical Research